Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug trial cut short after early testing

NCT ID NCT06488716

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called RO7759065, alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

12 people

The number who actually took part.

Started

Dec 2024

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Life expectancy at least 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate hematologic and end-organ function * Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1 * Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy * Availability of representative tumor specimens required for patients in select cohorts. Exclusion Criteria: * Women who are pregnant or breastfeeding * Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment * Active hepatitis B or C or tuberculosis * Positive test for human immunodeficiency virus (HIV) infection * Acute or chronic active Epstein-Barr virus (EBV) infection at screening * Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7759065 infusion * Primary, untreated, or active central nervous system (CNS) metastases * Active or history of autoimmune disease or immune deficiency * Prior allogeneic stem cell or organ transplantation * Any history of a Grade 3 immune-mediated adverse event attributed to prior cancer immunotherapy that resulted in permanent discontinuation of that agent * Any history of a Grade 4 immune-mediated adverse event attributed to prior cancer immunotherapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumour are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumour

Contacts and locations

Locations

  • British Columbia Cancer Agency

    Vancouver, British Columbia, V5Z 4R2, Canada

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra

    Pamplona, Navarre, 31008, Spain

  • Clinica Universidad de Navarra-Madrid

    Madrid, 28027, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2MR, Canada

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08901, United States

  • Sir Mortimer B Davis Jewish General Hospital-3755 Cote Sainte-Catherine

    Montreal, Quebec, H3T 1E2, Canada

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, 2010, Australia

  • Tennesse Oncology - NASH - SCRI - PPDS

    Chattanooga, Tennessee, 37404-1130, United States

  • University of Colorado

    Aurora, Colorado, 80045-2517, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.